CoChat

Antigen Presenting Cell Mimetic Lipid Nanoparticles for Rapid mRNA CAR T Cell Cancer Immunotherapy

Metzloff, Ann E., Padilla, Marshall S., Gong, Ningqiang, Billingsley, Margaret M., Han, Xuexiang, Merolle, Maria, Mai, David, Figueroa‐Espada, Christian G., Thatte, Ajay S., Haley, Rebecca M., Mukalel, Alvin J., Hamilton, Alex G., Alameh, Mohamad‐Gabriel, Weissman, Drew, Sheppard, Neil C., June, Carl H., Mitchell, Michael J. · 2024 · Advanced Materials
Cited by 68

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

Chimeric antigen receptor (CAR) T cell therapy has achieved remarkable clinical success in the treatment of hematological malignancies. However, producing these bespoke cancer‐killing cells is a complicated ex vivo process involving leukapheresis, artificial T cell activation, and CAR construct introduction. The activation step requires the engagement of CD3/TCR and CD28 and is vital for T cell transfection and differentiation. Though antigen‐presenting cells (APCs) facilitate activation in vivo, ex vivo activation relies on antibodies against CD3 and CD28 conjugated to magnetic beads. While effective, this artificial activation adds to the complexity of CAR T cell production as the beads must be removed prior to clinical implementation. To overcome this challenge, this work develops activating lipid nanoparticles (aLNPs) that mimic APCs to combine the activation of magnetic beads and the transfection capabilities of LNPs. It is shown that aLNPs enable one‐step activation and transfection of primary human T cells with the resulting mRNA CAR T cells reducing tumor burden in a murine xenograft model, validating aLNPs as a promising platform for the rapid production of mRNA CAR T cells.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/adma.202313226

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

2 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 57

  1. FDA D. I. S. C. O. Burst Edition: FDA Approval of Breyanzi (Lisocabtagene Maraleucel) for Second‐Line Treatment of Large B‐Cell Lymphoma FDA 2022.
  2. FDA D. I. S. C. O. Burst Edition: FDA Approval of ABECMA (Idecabtagene Vicleucel) the First FDA Approved Cell‐Based Gene Therapy for the Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma FDA 2021.
  3. FDA D. I. S. C. O. Burst Edition: FDA Approval of CARVYKTI (Ciltacabtagene Autoleucel) for the Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma after Four or More Prior Lines of Therapy Including a Proteasome Inhibitor an Immunomodulatory Agent and an Anti‐CD38 Monoclonal Antibody FDA 2022.
  4. 10.1038/s41586-023-05707-3 · DOI · Paper page
  5. 10.1056/NEJMoa1610497 · DOI · Paper page
  6. 10.1126/scitranslmed.aaa0984 · DOI · Paper page
  7. 10.1038/s41419-017-0238-6 · DOI
  8. 10.1038/s41591-020-1039-5 · DOI · Paper page
  9. 10.1080/17474086.2016.1183479 · DOI
  10. 10.1038/mto.2016.11 · DOI · Paper page
  11. 10.1016/j.annonc.2020.10.478 · DOI · Paper page
  12. 10.1056/NEJMoa1407222 · DOI · Paper page
  13. 10.1038/s41586-021-04390-6 · DOI · Paper page
  14. 10.1016/j.jaip.2021.10.037 · DOI
  15. 10.1089/hum.2011.070 · DOI · Paper page
  16. 10.1038/gt.2015.4 · DOI
  17. 10.1089/hum.2018.145 · DOI · Paper page
  18. 10.1038/s41467-020-19486-2 · DOI · Paper page
  19. 10.1021/acs.nanolett.9b04246 · DOI · Paper page
  20. 10.1021/acs.nanolett.1c02503 · DOI · Paper page
  21. 10.3390/ijms21186514 · DOI · Paper page
  22. 10.1007/978-1-0716-0146-4_7 · DOI
  23. 10.1158/2326-6066.CIR-14-0051 · DOI · Paper page
  24. 10.1158/0008-5472.CAN-10-2880 · DOI · Paper page
  25. 10.1158/2326-6066.CIR-13-0170 · DOI · Paper page
  26. 10.1016/j.biotechadv.2021.107760 · DOI
  27. 10.1053/j.gastro.2018.03.029 · DOI · Paper page
  28. 10.1158/2326-6066.CIR-17-0189 · DOI · Paper page
  29. 10.1073/pnas.1809671115 · DOI · Paper page
  30. 10.1016/j.canlet.2019.04.040 · DOI · Paper page
  31. 10.1038/s41467-021-27493-0 · DOI · Paper page
  32. 10.1016/S0022-1759(03)00010-3 · DOI · Paper page
  33. 10.2217/nnm.13.98 · DOI
  34. 10.1016/j.nano.2013.06.015 · DOI · Paper page
  35. 10.1016/j.biomaterials.2013.09.050 · DOI · Paper page
  36. 10.1016/j.tibtech.2015.07.001 · DOI
  37. 10.1002/smll.201402369 · DOI · Paper page
  38. 10.1038/s41598-020-74595-8 · DOI
  39. 10.1016/j.actbio.2023.02.023 · DOI
  40. 10.1021/acs.nanolett.5b02497 · DOI · Paper page
  41. 10.1021/acsnano.5b02796 · DOI · Paper page
  42. 10.1016/j.ymthe.2021.06.004 · DOI · Paper page
  43. 10.1016/j.ymthe.2017.06.008 · DOI · Paper page
  44. 10.4049/jimmunol.1601494 · DOI
  45. 10.4049/jimmunol.161.10.5338 · DOI · Paper page
  46. 10.1038/s41467-019-13997-3 · DOI · Paper page
  47. 10.1186/s12964-021-00766-3 · DOI
  48. 10.1016/j.bj.2021.09.004 · DOI
  49. 10.1002/eji.202049055 · DOI
  50. 10.1097/00002371-200409000-00010 · DOI
  51. 10.1021/ja301621z · DOI · Paper page
  52. 10.1021/acs.nanolett.1c01353 · DOI · Paper page
  53. 10.1016/j.omtm.2018.11.010 · DOI · Paper page
  54. 10.1038/nnano.2014.84 · DOI · Paper page
  55. 10.1038/s41467-020-17029-3 · DOI · Paper page
  56. 10.1038/nprot.2009.22 · DOI · Paper page
  57. 10.1073/pnas.2218632120 · DOI

Cited by

See all 68

Metadata

Authors
Metzloff, A. E., Padilla, M. S., Gong, N., Billingsley, M. M., Han, X., Merolle, M., Mai, D., Figueroa‐Espada, C. G., Thatte, A. S., Haley, R. M., Mukalel, A. J., Hamilton, A. G., Alameh, M., Weissman, D., Sheppard, N. C., June, C. H., & Mitchell, M. J.
Affiliations
  • Department of Bioengineering School of Engineering and Applied Science University of Pennsylvania Philadelphia PA 19104 USA
  • Department of Pathobiology School of Veterinary Medicine University of Pennsylvania Philadelphia PA 19104 USA
  • Department of Medicine University of Pennsylvania Philadelphia PA 19104 USA
  • Abramson Cancer Center Perelman School of Medicine University of Pennsylvania Philadelphia PA 19104 USA
Venue
Advanced Materials
Publisher
Wiley
Published
2024-03-15
Volume
36
Issue
26
ISSN
  • 0935-9648
  • 1521-4095
Cited by
68
References
16
Language
en
Funders
Emerson Collective

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.